VitaNova Life Sciences Corp (YJGJ) Financial Ratio Screen

NYSE Healthcare United States USD 121M
INSUFFICIENT / NOT IMPLEMENTED*
Automated financial screen · activity assessed separately
VitaNova Life Sciences Corp (YJGJ) needs additional financial data before the automated screen can be completed. One or more financial fields are missing; this is not a negative screening result.

Track YJGJ screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

YJGJ financial screening at a glance

INSUFFICIENT / NOT IMPLEMENTED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
N/A
Not available vs 30%
Cash ratio
34.7%
Fail vs 30%
Receivables + cash
90.8%
Fail vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-08-31. Financial period used: April 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleMore financial data neededNo negative conclusion follows from missing data
FTSE/Yasaar-styleMore financial data neededNo negative conclusion follows from missing data
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodApril 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Distribution) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Yijia Group Corp. provides business consulting services in the United States, Hong Kong, China, and internationally. It operates through two segments; Consulting Service and Healthcare. The company offers consulting advisory services in management business, accounting, and financial services; anti-aging products; and healthcare products and health consultation services. The company was formerly known as Soldino Group Corp. and changed its name to Yijia Group Corp. in November 2018. Yijia Group Corp. was incorporated in 2017 and is based in New York, New York.

Sources to verify: Secondary company profile and classification · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from April 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI N/A 34.7%
/ 30%
90.8%
/ 30%
N/A INSUFFICIENT / NOT IMPLEMENTED*
FTSE N/A 34.7%
/ 33%
90.8%
/ 50%
N/A INSUFFICIENT / NOT IMPLEMENTED*

Financial Highlights

P/E Ratio
53.7
EPS
$0.09
P/B Ratio
21.2
Revenue
$3M
Growth: 46.2%
Beta
0.3
Low volatility
Current Ratio
5.3

Profitability

Gross Margin 60.0%
Operating Margin 23.2%
Net Margin 30.9%
Return on Equity (ROE) 58.8%
Return on Assets (ROA) 43.7%

Cash Flow & Balance Sheet

Operating Cash Flow$192,774
Free Cash Flow$192,774
Current Ratio5.3
Total Assets$2M

Price & Trading

Last Close$4.83
50-Day MA$4.83
200-Day MA$2.43
Avg Volume0
Beta0.3
52-Week Range
$0.42
$7.50

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period April 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About VitaNova Life Sciences Corp (YJGJ)

CEO
Ms. Qiuping Lu
Employees
1
Sector
Healthcare
Industry
Medical Distribution
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 121M
Currency
USD

Yijia Group Corp. provides business consulting services in the United States, Hong Kong, China, and internationally. It operates through two segments; Consulting Service and Healthcare. The company offers consulting advisory services in management business, accounting, and financial services; anti-aging products; and healthcare products and health consultation services. The company was formerly known as Soldino Group Corp. and changed its name to Yijia Group Corp. in November 2018. Yijia Group Corp. was incorporated in 2017 and is based in New York, New York.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is VitaNova Life Sciences Corp (YJGJ) halal to invest in?

The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is VitaNova Life Sciences Corp's debt ratio?

VitaNova Life Sciences Corp's debt ratio is not available in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are VitaNova Life Sciences Corp's key financial metrics?

VitaNova Life Sciences Corp has a market capitalization of USD 121M in its listing currency, trailing P/E ratio of 53.7, and revenue of $3M. The company maintains a gross margin of 60.0% and a net margin of 30.9%. Return on equity stands at 58.8%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: April 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.